Filter By:

IAVI Report

IAVI Report is a scientific publication that provides comprehensive and editorially independent coverage of HIV vaccine and prevention research, as well as the quest to develop vaccines and other preventive technologies to address other global health priorities. It features the voices and opinions of those leading these efforts and provides an unparalleled analysis of the latest scientific and policy research.

To see recent full issues of IAVI Report, click here.

To access archived issues of IAVI Report dating back to 1996, click here.

Subscribe now to receive IAVI Report right to your inbox.

Questions/comments? Email us at iavireport@iavi.org.

Key Words Search

Will AI help make better vaccine antigens?

Researchers are capitalizing on the role machine learning can play in sequencing proteins and potentially guiding the design of finely tuned vaccine antigens.

Marion Gruber, Changemaker

After more than three decades at the U.S. Food and Drug Administration, Marion Gruber is continuing her legacy of changing the way vaccines are licensed and distributed.

Progress in African Vaccine Manufacturing

Improving vaccine access and pandemic preparedness topped the agenda at a major public health gathering in Berlin.

It takes a
village

Exploring synergies between B- and T-cell vaccines to optimize the immune response to HIV.

Hitchhiking the mucosa

Brittany Hartwell and her lab are exploring new ways to transport vaccine proteins across mucosal barriers to trigger more protective immune responses against many pathogens, including HIV.

Powering up African data centers

A growing network of scientists and modelers are bringing local context to epidemiological research on the continent.

Lingering lessons from past pandemics

COVID-19 is no longer a global emergency, but two new books explain why this is a critical moment in our preparation for the next new pathogen.

A view from Zambia on HIV vaccine research

Despite several setbacks, Clive Michelo is as dedicated as ever to his research and engaging with the community where he lives and works.

Improving access to vaccines

COVID-19 offers some stark lessons on ensuring equitable access to vaccines, but there are still many obstacles and varying opinions on how best to ensure diagnostics, vaccines, and therapeutics are deployed more fairly in the next pandemic.

Vaccines against RSV are coming

After decades of research, structure-based design efforts are yielding effective vaccines against respiratory syncytial virus. Jason McLellan explains the breakthroughs that paved the way.

HIV with a touch of gray

More and more people living with HIV are over 50 years old, raising new questions about the science of aging in individuals on antiretroviral therapy.

Is stopping SARS-CoV-2 transmission an attainable goal?

Hundreds of next-generation COVID-19 vaccines are being explored, including many that are delivered mucosally to boost immune responses that could prevent infection or block transmission.

The end of
an era

Anthony Fauci leaves behind an unparalleled legacy of championing HIV/AIDS treatment, prevention, and cure efforts.

Vaccine vials filled, but Ebola outbreak may be finishing

An outbreak of the Sudan strain of Ebola virus in Uganda seems contained, for now, but hopes for a vaccine remain, as do expectations it will be needed.

Momentum
against malaria

Vaccines against malaria will not break records for speed. But after a century of research, two vaccines are poised to take on this old foe, with many other technologies also in the works.

Monkeypox: What went right and what went wrong?

Chris Beyrer, director of the Duke Global Health Institute and a renowned epidemiologist, discusses the monkeypox outbreak and the U.S. response.

New tools leading way to HIV cure

Two new techniques could help researchers better characterize the HIV reservoir and determine how well strategies aimed at eliminating it are working.

Upping the
antibody

Monoclonal antibodies against SARS-CoV-2 were developed faster than any other intervention, but their use remains limited. What can HIV researchers learn from this?

Exploring adjuvants to boost durability of mRNA vaccines

COVID-19 has validated the use of mRNA vaccines but researchers are still exploring how to improve the durability of the antibody responses they induce. Bali Pulendran discusses how adjuvants are one approach to achieving longer-lasting immune responses against COVID-19 and other pathogens.

Data cabinets
in the cloud

IAVI’s DataSpace platform is making the information collected in landmark studies more widely available to the research community.

mRNA vaccines: Manufacturing in Africa

A South African biotech aims to produce the first African-developed, African-made mRNA vaccine, and to train researchers and developers from 16 similar would-be vaccine makers to do the same. Part two of a three-part series.

Is the next pandemic really preventable?

COVID-19 has inspired many books about pandemic prevention. If anything, this latest pandemic should shore up our willingness to prevent, prepare for, and respond to future infectious disease outbreaks. But reports show the world isn’t any better prepared today than it was before.

Unraveling the mysteries of a vaccine vector

Persistence pays. After decades, researchers identify an unusual mechanism for how a potential HIV vaccine vector works in animals. Will it also work in humans?

mRNA:
An HIV vaccine platform?

For HIV, there are currently several formulations of experimental vaccines in early-stage human clinical trials. Apart from some overlap in strategy, they have one main thing in common — they rely on mRNA.

Jon Cohen on
covering COVID-19

When SARS-CoV-2 emerged, Jon Cohen simply did what he always does as a science journalist. But this time his work had a dual purpose — his process was also being filmed as part of the documentary How to Survive a Pandemic.

From the editor

A new
IAVI Report

The past, present, and future of IAVI

A conversation with Seth
Berkley and Mark Feinberg

40 years
of AIDS
vaccine
research

A timeline of major milestones in the decades-long effort to develop an HIV vaccine.

Vaccines:
adapting to
the times

Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.

About

Our Work

Our Science

News & Resources

©2023 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative^®, IAVI^®, and the IAVI logo^® are registered trademarks of the International AIDS Vaccine Initiative, Inc.